New Jersey Biotech Nets $50M+ BARDA Contract for Respiratory Candidate

Ea­gle Phar­ma­ceu­ti­cals is keep­ing an eye on Enalare Ther­a­peu­tics’ lead res­pi­ra­to­ry can­di­date, and ap­par­ent­ly, so is the US gov­ern­ment.

The New Jer­sey-based biotech struck a deal with BAR­DA worth up to $50.3 mil­lion to de­vel­op the lead com­pound, dubbed ENA-001, the com­pa­ny an­nounced on Tues­day. The can­di­date is de­signed to sim­u­late breath­ing and is meant to be used in emer­gency cas­es when treat­ing drug over­dos­es or res­pi­ra­to­ry de­pres­sion post-surgery.

Ac­cord­ing to Enalare, the first phase of the con­tract will give it $6 mil­lion to com­plete any ac­tions through its Phase I tri­al. The over­all award, which will be based on sev­er­al mile­stones in R&D and pro­duc­tion, will give fund­ing for tox­i­col­o­gy, hu­man tri­als, man­u­fac­tur­ing and reg­u­la­to­ry fil­ings.

Read the full article at: endpts.com